ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Promoter Jay Arvind Bhanushali acquired 1,387 equity shares of Aspira Pathlab & Diagnostics Ltd through market purchase, increasing their stake from 7.25% to 7.27%.
Promoter Jay Arvind Bhanushali acquired 1,387 shares of Aspira Pathlab & Diagnostics Ltd via an open-market transaction, increasing his stake by 0.02%.
Promoter Jay Arvind Bhanushali acquired 74 shares of Aspira Pathlab & Diagnostics Ltd via market purchase on September 10, 2026.
Aspira Pathlab approved raising funds of up to ₹65 Crore via a Rights Issue to eligible shareholders. A committee was constituted to oversee the process.
Aspira Pathlab will hold a board meeting on 12 Sep 2026 to consider a capital raise via preferential issue, private placement, or rights issue. No amount or terms are yet specified.
Promoter Jay Arvind Bhanushali acquired 957 shares of Aspira Pathlab & Diagnostics Ltd via market purchase for ₹0.01 Crore.
Jay Arvind Bhanushali (Promoter) acquired 623 equity shares of Aspira Pathlab & Diagnostics Ltd via open market, increasing his holding slightly.
Aspira Pathlab & Diagnostics has dispatched the annual report web-link to shareholders who haven't registered their email addresses, in compliance with SEBI Regulation 36(1)(b).
Aspira Pathlab & Diagnostics Ltd has submitted its 53rd Annual Report and AGM Notice for the financial year 2025-26 to the exchange.
Aspira Pathlab & Diagnostics Ltd announced its 53rd Annual General Meeting to be held on September 25, 2026, with associated book closure and e-voting dates.
Promoter Jay Arvind Bhanushali acquired 332 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. This insider trading disclosure reports a value of ₹0.0029 Crore.
Jay Arvind Bhanushali, a promoter of Aspira Pathlab & Diagnostics Ltd, acquired 332 equity shares through the open market. This transaction increased the promoter's total holding from 7.23% to 7.24%.
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.2 Cr (+19.2% YoY) and net profit of ₹0 Cr for Q1 FY27.
Aspira Pathlab & Diagnostics will hold a board meeting on August 12, 2026, to approve its Q1 financial results and discuss a potential fund-raising proposal.
Mr. Pankaj Jashwant Shah has resigned as Managing Director and Chief Executive Director of Aspira Pathlab & Diagnostics Limited, effective from August 03, 2026.
Mr. Vaibhav Odhekar has resigned as Additional Executive Director of Aspira Pathlab & Diagnostics Limited, effective from the close of business hours on July 25, 2026.
Aspira Pathlab & Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per regulatory requirements.
Aspira Pathlab reclassified Mr. Nikunj Mange and Mr. Jay Bhanushali as Promoters post-Open Offer. This change in promoter category may impact governance and control dynamics.
Shraddha Jagdish Bhanushali and PACs acquired 22,82,507 shares (22.18% stake) via an open offer. This increases the promoter group's total holding to 46.00%.
Promoter Deepali Arvind Bhanushali acquired 85,443 shares (0.83%) in Aspira Pathlab via an open offer. This increases the promoter group's total stake to 46.00%.
Promoter group acquired 22.18% stake in Aspira Pathlab via an open offer. This increases their holding to 46%, signaling consolidation of control.
Aspira Pathlab & Diagnostics filed its Annual Secretarial Compliance Report for FY2026. The report by independent auditors confirms company compliance with SEBI regulatory requirements.
Aspira Pathlab appointed Mr. Vaibhav Odhekar as Executive Director for five years. Mrs. Neetu Maurya joins as Company Secretary, strengthening corporate governance and leadership.
Aspira Pathlab & Diagnostics Ltd reported revenue from operations of ₹6.5 Cr (+12.1% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.
Aspira Pathlab approved its audited standalone financial results for the year ended March 31, 2026. The board also appointed new management and an internal auditor.
Aspira Pathlab & Diagnostics scheduled a board meeting on May 23, 2026. Directors will consider audited financial results for the quarter and year ended March 2026.
Aspira Pathlab & Diagnostics Ltd informed BSE that it does not qualify as a Large Corporate for FY 2025-26 under SEBI criteria. Consequently, the mandatory requirement to raise 25% of incremental borrowings through debt securities is not applicable. The company reported nil incremental borrowing and nil debt security issuance for the period.
Aspira Pathlab & Diagnostics Limited confirmed it is not identified as a Large Corporate as of March 31, 2026. The company reported zero outstanding borrowings and filed the disclosure in compliance with SEBI debt-raising norms for large entities.
Aspira Pathlab & Diagnostics Ltd's Independent Director Committee has recommended an Open Offer for the acquisition of 26,76,180 shares (26% stake) at ₹55 per share. The ₹14.72 Crore offer is led by Mr. Arvind Karsandas Bhanushali and others. The IDC considers the offer fair and reasonable based on SEBI valuation parameters.